Stay updated on Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the previous content, replacing the study details and navigation with an access-denied message. This indicates a site-level access restriction rather than updates to the trial information.SummaryDifference19%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision label changed from v3.6.5 to v3.6.6. This reflects a minor maintenance update to the page metadata and does not alter study details, eligibility, or results.SummaryDifference0.1%

- Check45 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, indicating a minor maintenance/update to the page. This change does not appear to modify study details or eligibility criteria.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page’s revision label updated from v3.6.3 to v3.6.4, indicating a new version of the page metadata rather than a modification to the study details.SummaryDifference0.1%

- Check88 days agoChange DetectedUpdate to site revision: Revision: v3.6.3 replaces the prior Revision: v3.6.2. This appears to be a behind-the-scenes platform update and does not modify study content or user workflows.SummaryDifference0.1%

- Check95 days agoChange DetectedA new revision tag v3.6.2 appears on the page, while the previous tag v3.6.0 is removed. This indicates an update to the page's revision/version rather than changes to study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Poly-ICLC in MRP Colon Cancer Clinical Trial page.